An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy

• Status: Enrolling by invitation
• Trial end date: 2026-08-10
• Target enrollment: 0
• Participant gender: Male

Summary

The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sarepta Therapeutics; Sarepta Therapeutics, Inc.

Criteria

Inclusion Criteria:

• Completed a clinical trial evaluating casimersen or golodirsen, per protocol.

• Is between 7 and 23 years of age, inclusive, at enrollment.

Other inclusion/exclusion criteria apply.